Open Access Full Text Article

RETRACTION

miR-132 Can Inhibit Glioma Cells Invasion and Migration by Target MMP16 in vitro [Retraction]

Wang H, Li X, Wu C, Wu Z, Li Y, Yang T, Chen G, Xie X, Huang Y, Du Z, Zhou YX. Onco Targets Ther. 2015;8:3211–3218

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding alleged image duplication in Figure 2A and Figure 4. Specifically,

- Figure 2A, panel U87 Normal appears to show duplication with parts of Figure 2A, panel U87 Pre-miR-132 NC.
- Figure 2A, panel SHG44 Anti-miR-132 appears to show duplicated regions within the same image.
- Figure 2A, panel A172 Pre-miR-132 appears to show duplicated regions within the same image.
- Figure 2A, panel SHG44 Pre-miR-132 appears to show duplicated regions within the same image.
- Figure 2A, panels U87 Normal and Anti-miR-132 NC appear to show duplicated regions with Figure 4A, panel U87 Mock from Yang et al (2014) (https://doi.org/10.1111/cas.12351).
- Figure 2A, panel U87 Anti-miR-132 appears to show duplication with parts of Figure 4A, panel U87 Negative from Yang et al (2014) (https://doi.org/10.1111/cas.12351).

The authors were contacted and did provide an explanation for the duplicated images, but it was not satisfactory. In addition, the authors did provide some original data but again it was not satisfactory, and the findings of the paper were deemed to be invalid.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

215

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S364549

Received: 1 March 2022 Accepted: 1 March 2022 Published: 4 March 2022

OncoTargets and Therapy 2022:15 215

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com. the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).